Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Vertex Pharmaceuticals is moving beyond its cystic fibrosis small-molecule franchise. The company is purchasing the Cambridge, Massachusetts–based start-up Semma Therapeutics, which is designing stem cell therapies for type 1 diabetes, for $950 million in cash. Semma has a method for turning stem cells into insulin-secreting β cells, which it licensed from Harvard University’s Douglas Melton. The company plans to start clinical trials of its β cell injections next year.
This article has been sent to the following recipient: